|
市場調查報告書
自閉症譜系障礙:高未滿足需求創造出很大的市場機會
Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities
|
自閉症譜系障礙:高未滿足需求創造出很大的市場機會 是由出版商Decision Resources, Inc.在2011年06月所出版的。
這份英文市場調查報告書價格從美金9200起跳。
自閉症譜系障礙(ASD)的治療以行動療法為主，許多患者都將藥物治療當作治療的一個環節。目前FDA核可的治療藥只有兩種，據專家認為此兩種藥劑都非治療上的第一線選擇。這種沒有可利用治療法的情形，形成了對企業來說的莫大機會。
本報告提供自閉症譜系障礙的概要與美國到2020年為止的10年的免疫學，診斷標準，新興治療方法等彙整資料，為您概述為以下內容。
摘要整理
簡介
自閉症譜系障礙:定義與症狀
病因
診斷形態
免疫學和患者人口
治療方法
- 行動療法和發達療法
- 藥理學的治療
- 非定型抗精神病藥
- 選擇性血清再吸收抑制劑
- 刺激劑
- 其他藥物治療
新興治療方法
- Seaside Therapeutics的STX-209
- Curemark的CM-AT
- Forest Laboratories/Merz的Mematine
- BioMarin的Kuvan
- 針對不穩定的X症狀的新興代謝型谷氨酸受體拮抗劑
自閉症譜系障礙市場今後的預測
參考資訊
圖表
Abstract
Introduction:
"Oh, this field is going to transform. I think you' re going to actually see
new drugs come to market based on novel mechanisms with good preclinical
evidence." So one interviewed thought leader predicts. Although behavioral
therapy remains the cornerstone of autism spectrum disorders (ASD) treatment,
most thought leaders interviewed by Decision Resources indicate that the
majority of ASD patients (including a large number of patients with classic
autism) receive some form of drug therapy during the course of their
treatment. Only two agents have been FDA approved for the treatment of ASD
patients, but these are not the first choice of therapy for many of our
interviewed experts. Given the lack of available treatments, substantial
opportunity awaits a company that invests in new agents in this market.
Questions Answered in This Report:
- ASD is much more common in males than females. What is the male to
female ratio in prevalence? What is the present prevalent population in the
United States and the forecasted number of prevalent cases of ASD over the
next ten years? Is the prevalence of ASD increasing?
- Only two agents, both of which are antipsychotics, are currently approved
to treat patients with ASD - Janssen' s (Johnson & Johnson' s) Risperdal
(risperidone) and Bristol-Myers Squibb/Otsuka Pharmaceutical' s Abilify
(Aripiprazole). What do interviewed thought leaders say about use of these
agents? Are these treatments effective in ASD patients? What are the sales of
Risperdal and Abilify in this market? What factors influence sales of these
two agents? What other drugs are prescribed for ASD patients?
- None of the current treatments for ASD address the core symptoms of the
disease. What are the emerging agents in the pipeline? Do any of these
address the core symptoms of ASD? Do any of them show promising results from
clinical trials? How do interviewed thought leaders perceive emerging
therapies?
- The DSM-IV criteria for ASD are being reviewed, and the final approved
DSM-V criteria are expected to be published in May 2013. How do the
proposed new diagnostic criteria differ from the existing criteria? What do
interviewed thought leaders say about the new proposed criteria?
Scope:
Primary research: Interviews with U.S. thought leaders who work closely
with children with ASD. Includes pediatric psychologists, psychiatrists, and
neurologists.
Epidemiology: Prevalent U.S. cases over a ten-year forecast period,
2010-2020; trends in prevalence.
Diagnostic criteria: Review of current diagnostic criteria and the
proposed DSM-V criteria for ASD.
Emerging therapies: Phase III: 1 drug; Phase II: 3 drugs; Phase I: 1
drug.
Select emerging therapies for fragile X syndrome: The link between
autism spectrum disorders and fragile X syndrome and clinical development for
fragile X syndrome: Phase III: 1 drug; Phase II/III: 1 drug; Phase II: 2 drugs.
U.S. market: 2010 brand sales attributable to use for autism spectrum
disorders; market considerations.
Table of Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Autism Spectrum Disorders: Definitions and Symptoms
- Current Diagnostic Criteria for ASD
- Proposed DSM-V Diagnostic Criteria for ASD
Etiology
- Genetic Causes of ASD
- Other Causes of ASD
Diagnosis Patterns
Epidemiology and Patient Populations
- Overview
- Disease Definition
- Methods
- Subpopulations
Treatment Approaches for Autistic Spectrum Disorder
- Behavioral and Developmental Therapies
- Pharmacological Therapies
- Atypical Antipsychotics
- Selective Serotonin Reuptake Inhibitors
- Stimulants
- Other Drug Treatments
Emerging Treatments for Autism Spectrum Disorders
- Seaside Therapeutics' STX-209
- Curemark' s CM-AT
- Forest Laboratories/Merz' s Memantine
- BioMarin' s Kuvan
- Emerging Metabotropic Glutamate Receptor Antagonists for Fragile X Syndrome
Market Outlook for Autism Spectrum Disorders
Bibliography
Tables
- 1. Thought-Leader Opinion on Autism Spectrum Disorders
- 2. Select Genes Associated with Autism Spectrum Disorders
- 3. Screening Tools Used for Diagnosis of Autism Spectrum Disorders
- 4. Emerging Therapies for the Treatment of Autism Spectrum Disorders
- 5. Select Emerging Therapies for Fragile X Syndrome
- 6. Sales of Key Brand Drugs to Treat Autism Spectrum Disorders in the
United States, 2010
Figures
- 1. Survey Results: Percentage of Surveyed Physicians Reporting That
Parents of Pediatric Patients Declined or Hesitated to Vaccinate Children
Because of Fears of Autism or Other Adverse Outcomes
- 2. Survey Results: Percentage of Surveyed Physicians Reporting Whether
Parents Are More Open to Vaccination Given That Studies Linking Vaccines with
Autism Have Been Discredited
- 3. Number of Total Prevalent Cases of Autism Spectrum Disorders in the
United States, 2010-2020
|
